{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:06:40Z","timestamp":1793394400926,"version":"4.5.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-025-04123-5","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T19:10:38Z","timestamp":1763493038000},"page":"1476-1483","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Role of surgery in metastatic gastric cancer"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4188-1740","authenticated-orcid":false,"given":"Israel","family":"Manzanedo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Est\u00edbalitz","family":"P\u00e9rez-Viejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Pereira P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"issue":"3","key":"4123_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"4123_CR2","doi-asserted-by":"publisher","first-page":"114062","DOI":"10.1016\/j.ejca.2024.114062","volume":"204","author":"TE Kroese","year":"2024","unstructured":"Kroese TE, Bronzwaer S, van Rossum PSN, Schoppman SF, Deseyne PRAJ, van Cutsem E, et al. European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4). Eur J Cancer. 2024;204:114062. https:\/\/doi.org\/10.1016\/j.ejca.2024.114062.","journal-title":"Eur J Cancer"},{"issue":"10251","key":"4123_CR3","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","volume":"396","author":"EC Smyth","year":"2020","unstructured":"Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396(10251):635\u201348. https:\/\/doi.org\/10.1016\/S0140-6736(20)31288-5.","journal-title":"Lancet"},{"issue":"6","key":"4123_CR4","doi-asserted-by":"publisher","first-page":"109731","DOI":"10.1016\/j.ejso.2025.109731","volume":"51","author":"A Mariani","year":"2025","unstructured":"Mariani A, Triantafyllou E, Kepenekian V, Zaanan A, Glehen O, Karoui M. Management of peritoneal gastric metastasis: an update. Eur J Surg Oncol. 2025;51(6):109731. https:\/\/doi.org\/10.1016\/j.ejso.2025.109731.","journal-title":"Eur J Surg Oncol"},{"issue":"3","key":"4123_CR5","doi-asserted-by":"publisher","first-page":"673","DOI":"10.3390\/cancers16030673","volume":"16","author":"I Yasufuku","year":"2024","unstructured":"Yasufuku I, Tsuchiya H, Fujibayashi S, Okumura N, Sengoku Y, Fukada M, et al. Oligometastasis of gastric cancer: a review. Cancers. 2024;16(3):673.","journal-title":"Cancers"},{"issue":"9742","key":"4123_CR6","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687\u201397. https:\/\/doi.org\/10.1016\/S0140-6736(10)61121-X.","journal-title":"Lancet"},{"issue":"10294","key":"4123_CR7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(21)00797-2.","journal-title":"Lancet"},{"issue":"2","key":"4123_CR8","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"YK Kang","year":"2022","unstructured":"Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC, Chung HC, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23(2):234\u201347. https:\/\/doi.org\/10.1016\/S1470-2045(21)00692-6.","journal-title":"Lancet Oncol"},{"issue":"10142","key":"4123_CR9","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0140-6736(18)31257-1","volume":"392","author":"K Shitara","year":"2018","unstructured":"Shitara K, \u00d6zg\u00fcro\u011flu M, Bang YJ, Di Bartolomeo M, Mandal\u00e0 M, Ryu MH, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018;392(10142):123\u201333. https:\/\/doi.org\/10.1016\/S0140-6736(18)31257-1.","journal-title":"Lancet"},{"issue":"6","key":"4123_CR10","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.3390\/cancers15061777","volume":"15","author":"I Manzanedo","year":"2023","unstructured":"Manzanedo I, Pereira F, P\u00e9rez-Viejo E, Serrano \u00c1. Gastric cancer with peritoneal metastases: current status and prospects for treatment. Cancers. 2023;15(6):1777. https:\/\/doi.org\/10.3390\/cancers15061777.","journal-title":"Cancers"},{"issue":"10","key":"4123_CR11","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","volume":"33","author":"F Lordick","year":"2022","unstructured":"Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):1005\u201320. https:\/\/doi.org\/10.1016\/j.annonc.2022.07.004.","journal-title":"Ann Oncol"},{"issue":"1","key":"4123_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-022-01331-8","volume":"26","author":"Japanese Gastric Cancer Association","year":"2023","unstructured":"Japanese Gastric Cancer Association. Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition). Gastric Cancer. 2023;26(1):1\u201325.","journal-title":"Gastric Cancer"},{"issue":"3","key":"4123_CR13","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.3390\/curroncol31030109","volume":"31","author":"M Acs","year":"2024","unstructured":"Acs M, Piso P, Glockzin G. Peritoneal metastatic gastric cancer: local treatment options and recommendations. Curr Oncol. 2024;31(3):1445\u201359. https:\/\/doi.org\/10.3390\/curroncol31030109.","journal-title":"Curr Oncol"},{"issue":"5","key":"4123_CR14","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.clinre.2020.02.003","volume":"44","author":"P Jin","year":"2020","unstructured":"Jin P, Ji X, Tian Y. Surgical management of oligometastatic disease in gastric cancer. Clin Res Hepatol Gastroenterol. 2020;44(5):638\u201345. https:\/\/doi.org\/10.1016\/j.clinre.2020.02.003.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"21","key":"4123_CR15","doi-asserted-by":"publisher","first-page":"5200","DOI":"10.3390\/cancers14215200","volume":"14","author":"TO Goetze","year":"2022","unstructured":"Goetze TO, Al-Batran SE. Perspectives on the management of oligometastatic disease in esophago-gastric cancer. Cancers. 2022;14(21):5200.","journal-title":"Cancers"},{"key":"4123_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.21037\/tgh.2019.10.04","volume":"5","author":"J Desiderio","year":"2020","unstructured":"Desiderio J, Trastulli S, D\u2019Andrea V, Parisi A. Enhanced recovery after surgery for gastric cancer (ERAS-GC): optimizing patient outcome. Transl Gastroenterol Hepatol. 2020;5:11.","journal-title":"Transl Gastroenterol Hepatol"},{"issue":"4","key":"4123_CR17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/jso.21068","volume":"98","author":"AG Portilla","year":"2008","unstructured":"Portilla AG, Shigeki K, Dario B, Marcello D. The intraoperative staging systems in the management of peritoneal surface malignancy. J Surg Oncol. 2008;98(4):228\u201331.","journal-title":"J Surg Oncol"},{"issue":"4","key":"4123_CR18","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1002\/jso.21072","volume":"98","author":"S Gonz\u00e1lez-Moreno","year":"2008","unstructured":"Gonz\u00e1lez-Moreno S, Kusamura S, Baratti D, Deraco M. Postoperative residual disease evaluation in the locoregional treatment of peritoneal surface malignancy. J Surg Oncol. 2008;98(4):237\u201341. https:\/\/doi.org\/10.1002\/jso.21072.","journal-title":"J Surg Oncol"},{"issue":"10389","key":"4123_CR19","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401(10389):1655\u201368.","journal-title":"Lancet"},{"issue":"2","key":"4123_CR20","doi-asserted-by":"publisher","first-page":"434","DOI":"10.4251\/wjgo.v14.i2.434","volume":"14","author":"M Chevallay","year":"2022","unstructured":"Chevallay M, Wassmer CH, Iranmanesh P, Jung MK, M\u00f6nig SP. Multimodal treatment in oligometastatic gastric cancer. World J Gastrointest Oncol. 2022;14(2):434\u201349. https:\/\/doi.org\/10.4251\/wjgo.v14.i2.434.","journal-title":"World J Gastrointest Oncol"},{"issue":"1","key":"4123_CR21","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.asjsur.2017.09.005","volume":"42","author":"T Ryu","year":"2019","unstructured":"Ryu T, Takami Y, Wada Y, Tateishi M, Matsushima H, Yoshitomi M, et al. Oncological outcomes after hepatic resection and\/or surgical microwave ablation for liver metastasis from gastric cancer. Asian J Surg. 2019;42(1):100\u20135.","journal-title":"Asian J Surg"},{"issue":"2","key":"4123_CR22","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s10120-016-0604-6","volume":"20","author":"SR Markar","year":"2017","unstructured":"Markar SR, Mackenzie H, Mikhail S, Mughal M, Preston SR, Maynard ND, et al. Surgical resection of hepatic metastases from gastric cancer: outcomes from national series in England. Gastric Cancer. 2017;20(2):379\u201386.","journal-title":"Gastric Cancer"},{"issue":"2","key":"4123_CR23","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1007\/s10120-017-0730-9","volume":"21","author":"H Shirasu","year":"2018","unstructured":"Shirasu H, Tsushima T, Kawahira M, Kawai S, Kawakami T, Kito Y, et al. Role of hepatectomy in gastric cancer with multiple liver-limited metastases. Gastric Cancer. 2018;21(2):338\u201344.","journal-title":"Gastric Cancer"},{"key":"4123_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ctrv.2018.05.010","volume":"69","author":"F Montagnani","year":"2018","unstructured":"Montagnani F, Crivelli F, Aprile G, Vivaldi C, Pecora I, De Vivo R, et al. Long-term survival after liver metastasectomy in gastric cancer: systematic review and meta-analysis of prognostic factors. Cancer Treat Rev. 2018;69:11\u201320. https:\/\/doi.org\/10.1016\/j.ctrv.2018.05.010.","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"4123_CR25","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.3390\/jcm10051141","volume":"10","author":"G Marte","year":"2021","unstructured":"Marte G, Tufo A, Steccanella F, Marra E, Federico P, Petrillo A, et al. Efficacy of surgery for the treatment of gastric cancer liver metastases: a systematic review of the literature and meta-analysis of prognostic factors. J Clin Med. 2021;10(5):1141. https:\/\/doi.org\/10.3390\/jcm10051141.","journal-title":"J Clin Med"},{"key":"4123_CR26","doi-asserted-by":"publisher","first-page":"103313","DOI":"10.1016\/j.critrevonc.2021.103313","volume":"163","author":"S Granieri","year":"2021","unstructured":"Granieri S, Altomare M, Bruno F, Paleino S, Bonomi A, Germini A, et al. Surgical treatment of gastric cancer liver metastases: systematic review and meta-analysis of long-term outcomes and prognostic factors. Crit Rev Oncol Hematol. 2021;163:103313. https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103313.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"4123_CR27","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1186\/s12885-017-3918-9","volume":"17","author":"SE Al-Batran","year":"2017","unstructured":"Al-Batran SE, Goetze TO, Mueller DW, Vogel A, Winkler M, Lorenzen S, et al. The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction\u2014a phase III trial of the German AIO\/CAO-V\/CAOGI. BMC Cancer. 2017;17(1):893.","journal-title":"BMC Cancer"},{"issue":"17_suppl","key":"4123_CR28","doi-asserted-by":"publisher","first-page":"LBA4001-LBA4001","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA4001","volume":"42","author":"SE Al-Batran","year":"2024","unstructured":"Al-Batran SE, Lorenzen S, Riera J, Caca K, Mueller C, Stange DE, et al. Effect of chemotherapy\/targeted therapy alone vs. chemotherapy\/targeted therapy followed by radical surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction: the IKF-575\/RENAISSANCE phase III trial. J Clin Oncol. 2024;42(17_suppl):LBA4001\u2013LBA4001.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4123_CR29","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1245\/s10434-024-16318-1","volume":"32","author":"IA Ziogas","year":"2025","unstructured":"Ziogas IA, Thielen ON, Ghaffar SA, Yee EJ, Khomiak A, Durden JA, et al. The role of metastasectomy in patients with liver-only metastases from gastric adenocarcinoma. Ann Surg Oncol. 2025;32(1):391\u20138.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"4123_CR30","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s10120-024-01479-5","volume":"27","author":"P Morgagni","year":"2024","unstructured":"Morgagni P, Bencivenga M, Carneiro F, Cascinu S, Derks S, Di Bartolomeo M, et al. International consensus on the management of metastatic gastric cancer: step by step in the foggy landscape: Bertinoro Workshop, November 2022. Gastric Cancer. 2024;27(4):649\u201371.","journal-title":"Gastric Cancer"},{"issue":"2","key":"4123_CR31","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/ags3.12515","volume":"6","author":"K Yoshida","year":"2022","unstructured":"Yoshida K, Yasufuku I, Terashima M, Young Rha S, Moon Bae J, Li G, et al. International retrospective cohort study of conversion therapy for stage IV gastric cancer 1 (CONVO-GC-1). Ann Gastroenterol Surg. 2022;6(2):227\u201340. https:\/\/doi.org\/10.1002\/ags3.12515.","journal-title":"Ann Gastroenterol Surg"},{"issue":"8","key":"4123_CR32","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.ejso.2016.03.016","volume":"42","author":"Y Yonemura","year":"2016","unstructured":"Yonemura Y, Canbay E, Li Y, Coccolini F, Glehen O, Sugarbaker PH, et al. A comprehensive treatment for peritoneal metastases from gastric cancer with curative intent. Eur J Surg Oncol (EJSO). 2016;42(8):1123\u201331. https:\/\/doi.org\/10.1016\/j.ejso.2016.03.016.","journal-title":"Eur J Surg Oncol (EJSO)"},{"issue":"11","key":"4123_CR33","doi-asserted-by":"publisher","first-page":"3774","DOI":"10.3390\/jcm12113774","volume":"12","author":"I Manzanedo","year":"2023","unstructured":"Manzanedo I, Pereira F, Cascales-Campos P, Mu\u00f1oz-Casares C, Asensio E, Torres-Melero J, et al. Treatment of peritoneal surface malignancies by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in Spain: results of the National Registry of the Spanish Group of Peritoneal Oncologic Surgery (REGECOP). J Clin Med. 2023;12(11):3774. https:\/\/doi.org\/10.3390\/jcm12113774.","journal-title":"J Clin Med"},{"issue":"1","key":"4123_CR34","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/00000658-199501000-00004","volume":"221","author":"PH Sugarbaker","year":"1995","unstructured":"Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221(1):29\u201342.","journal-title":"Ann Surg"},{"issue":"1","key":"4123_CR35","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1272\/jnms.67.5","volume":"67","author":"PH Sugarbaker","year":"2000","unstructured":"Sugarbaker PH. It\u2019s what the surgeon doesn\u2019t see that kills the patient. J Nippon Med Sch. 2000;67(1):5\u20138.","journal-title":"J Nippon Med Sch"},{"issue":"5","key":"4123_CR36","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/annonc\/mdl428","volume":"18","author":"TD Yan","year":"2007","unstructured":"Yan TD, Welch L, Black D, Sugarbaker PH. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol. 2007;18(5):827\u201334. https:\/\/doi.org\/10.1093\/annonc\/mdl428.","journal-title":"Ann Oncol"},{"issue":"1","key":"4123_CR37","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S1470-2045(05)70539-8","volume":"7","author":"PH Sugarbaker","year":"2006","unstructured":"Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol. 2006;7(1):69\u201376. https:\/\/doi.org\/10.1016\/S1470-2045(05)70539-8.","journal-title":"Lancet Oncol"},{"issue":"1","key":"4123_CR38","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1186\/s12885-022-09572-7","volume":"22","author":"F Pereira","year":"2022","unstructured":"Pereira F, Serrano A, Manzanedo I, P\u00e9rez-Viejo E, Gonz\u00e1lez-Moreno S, Gonz\u00e1lez-Bay\u00f3n L, et al. GECOP-MMC: phase IV randomized clinical trial to evaluate the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) with mytomicin-C after complete surgical cytoreduction in patients with colon cancer peritoneal metastases. BMC Cancer. 2022;22(1):536.","journal-title":"BMC Cancer"},{"issue":"9","key":"4123_CR39","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1245\/s10434-008-9966-2","volume":"15","author":"VJ Verwaal","year":"2008","unstructured":"Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15(9):2426\u201332.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"4123_CR40","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","volume":"22","author":"F Qu\u00e9net","year":"2021","unstructured":"Qu\u00e9net F, Elias D, Roca L, Go\u00e9r\u00e9 D, Ghouti L, Pocard M, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):256\u201366. https:\/\/doi.org\/10.1016\/S1470-2045(20)30599-4.","journal-title":"Lancet Oncol"},{"issue":"10","key":"4123_CR41","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S1470-2045(23)00396-0","volume":"24","author":"SL Aronson","year":"2023","unstructured":"Aronson SL, Lopez-Yurda M, Koole SN, van Schagen Leeuwen JH, Schreuder HWR, Hermans RHM, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial. Lancet Oncol. 2023;24(10):1109\u201318.","journal-title":"Lancet Oncol"},{"issue":"3","key":"4123_CR42","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJMoa1708618","volume":"378","author":"WJ van Driel","year":"2018","unstructured":"van Driel WJ, Koole SN, Sikorska K, van Schagen Leeuwen JH, Schreuder HWR, Hermans RHM, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230\u201340.","journal-title":"N Engl J Med"},{"issue":"9","key":"4123_CR43","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1245\/s10434-010-1039-7","volume":"17","author":"O Glehen","year":"2010","unstructured":"Glehen O, Gilly FN, Arvieux C, Cotte E, Boutitie F, Mansvelt B, et al. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 2010;17(9):2370\u20137.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"4123_CR44","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s10120-019-00978-0","volume":"23","author":"B Rau","year":"2020","unstructured":"Rau B, Brandl A, Piso P, Pelz J, Busch P, Demtr\u00f6der C, et al. Peritoneal metastasis in gastric cancer: results from the German database. Gastric Cancer. 2020;23(1):11\u201322.","journal-title":"Gastric Cancer"},{"issue":"8","key":"4123_CR45","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1245\/s10434-019-07450-4","volume":"26","author":"I Manzanedo","year":"2019","unstructured":"Manzanedo I, Pereira F, Rihuete Caro C, P\u00e9rez-Viejo E, Serrano \u00c1, Guti\u00e9rrez Calvo A, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for gastric cancer with peritoneal carcinomatosis: multicenter study of Spanish group of peritoneal oncologic surgery (GECOP). Ann Surg Oncol. 2019;26(8):2615\u201321.","journal-title":"Ann Surg Oncol"},{"issue":"13","key":"4123_CR46","doi-asserted-by":"publisher","first-page":"9060","DOI":"10.1245\/s10434-021-10157-0","volume":"28","author":"L Marano","year":"2021","unstructured":"Marano L, Marrelli D, Sammartino P, Biacchi D, Graziosi L, Marino E, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for gastric cancer with synchronous peritoneal metastases: multicenter study of \u00abItalian Peritoneal Surface Malignancies Oncoteam-S.I.C.O.\u00bb. Ann Surg Oncol. 2021;28(13):9060\u201370.","journal-title":"Ann Surg Oncol"},{"issue":"23","key":"4123_CR47","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1200\/JCO.18.01688","volume":"37","author":"PE Bonnot","year":"2019","unstructured":"Bonnot PE, Piessen G, Kepenekian V, Decullier E, Pocard M, Meunier B, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis. J Clin Oncol. 2019;37(23):2028\u201340.","journal-title":"J Clin Oncol"},{"issue":"6","key":"4123_CR48","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1245\/s10434-011-1631-5","volume":"18","author":"XJ Yang","year":"2011","unstructured":"Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Cheng FL, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011;18(6):1575\u201381.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"4123_CR49","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/jso.23633","volume":"110","author":"U Rudloff","year":"2014","unstructured":"Rudloff U, Langan RC, Mullinax JE, Beane JD, Steinberg SM, Beresnev T, et al. Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial. J Surg Oncol. 2014;110(3):275\u201384. https:\/\/doi.org\/10.1002\/jso.23633.","journal-title":"J Surg Oncol"},{"issue":"12","key":"4123_CR50","doi-asserted-by":"publisher","first-page":"7528","DOI":"10.1245\/s10434-022-12312-7","volume":"29","author":"M Martins","year":"2022","unstructured":"Martins M, Santos-Sousa H, Ara\u00fajo F, Nogueiro J, Sousa-Pinto B. Impact of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer with peritoneal carcinomatosis: a systematic review and meta-analysis. Ann Surg Oncol. 2022;29(12):7528\u201337.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"4123_CR51","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1200\/JCO.22.02867","volume":"42","author":"B Rau","year":"2024","unstructured":"Rau B, Lang H, Koenigsrainer A, Gockel I, Rau HG, Seeliger H, et al. Effect of hyperthermic intraperitoneal chemotherapy on cytoreductive surgery in gastric cancer with synchronous peritoneal metastases: the phase III GASTRIPEC-I trial. J Clin Oncol. 2024;42(2):146\u201356.","journal-title":"J Clin Oncol"},{"issue":"11","key":"4123_CR52","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.3390\/cancers11111662","volume":"11","author":"AC Gamboa","year":"2019","unstructured":"Gamboa AC, Winer JH. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for gastric cancer. Cancers. 2019;11(11):1662.","journal-title":"Cancers"},{"issue":"11","key":"4123_CR53","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1016\/j.ejso.2018.06.036","volume":"44","author":"C Rihuete Caro","year":"2018","unstructured":"Rihuete Caro C, Manzanedo I, Pereira F, Carrion-Alvarez L, Serrano \u00c1, P\u00e9rez-Viejo E. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with gastric cancer and peritoneal carcinomatosis. Eur J Surg Oncol. 2018;44(11):1805\u201310. https:\/\/doi.org\/10.1016\/j.ejso.2018.06.036.","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"4123_CR54","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.21037\/jgo-20-232","volume":"12","author":"I Manzanedo","year":"2021","unstructured":"Manzanedo I, Pereira F, Serrano \u00c1, P\u00e9rez-Viejo E. Review of management and treatment of peritoneal metastases from gastric cancer origin. J Gastrointest Oncol. 2021;12(1):S20\u20139.","journal-title":"J Gastrointest Oncol"},{"issue":"12","key":"4123_CR55","doi-asserted-by":"publisher","first-page":"7244","DOI":"10.1245\/s10434-022-12383-6","volume":"29","author":"BD Badgwell","year":"2022","unstructured":"Badgwell BD. Don\u2019t call it a comeback\u2014HIPEC for gastric cancer. Ann Surg Oncol. 2022;29(12):7244\u20135.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"4123_CR56","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1186\/s12885-019-5640-2","volume":"19","author":"WJ Koemans","year":"2019","unstructured":"Koemans WJ, van der Kaaij RT, Boot H, Buffart T, Veenhof AAFA, Hartemink KJ, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy versus palliative systemic chemotherapy in stomach cancer patients with peritoneal dissemination, the study protocol of a multicentre randomised controlled trial (PERISCOPE II). BMC Cancer. 2019;19(1):420.","journal-title":"BMC Cancer"},{"issue":"1","key":"4123_CR57","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1245\/s10434-023-14415-1","volume":"31","author":"AL Sarvestani","year":"2024","unstructured":"Sarvestani AL, Gregory SN, Akmal SR, Hernandez JM, van der Sluis K, van Sandick JW. Gastrectomy + cytoreductive surgery + HIPEC for gastric cancer with peritoneal dissemination (PERISCOPE II). Ann Surg Oncol. 2024;31(1):28\u201330.","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"4123_CR58","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.ejso.2006.03.007","volume":"32","author":"Y Yonemura","year":"2006","unstructured":"Yonemura Y, Bandou E, Sawa T, Yoshimitsu Y, Endou Y, Sasaki T, et al. Neoadjuvant treatment of gastric cancer with peritoneal dissemination. Eur J Surg Oncol. 2006;32(6):661\u20135. https:\/\/doi.org\/10.1016\/j.ejso.2006.03.007.","journal-title":"Eur J Surg Oncol"},{"key":"4123_CR59","doi-asserted-by":"publisher","first-page":"148420","DOI":"10.1155\/2012\/148420","volume":"2012","author":"Y Yonemura","year":"2012","unstructured":"Yonemura Y, Elnemr A, Endou Y, Ishibashi H, Mizumoto A, Miura M, et al. Effects of neoadjuvant intraperitoneal\/systemic chemotherapy (bidirectional chemotherapy) for the treatment of patients with peritoneal metastasis from gastric cancer. Int J Surg Oncol. 2012;2012:148420. https:\/\/doi.org\/10.1155\/2012\/148420.","journal-title":"Int J Surg Oncol"},{"issue":"4","key":"4123_CR60","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1245\/s10434-013-3443-2","volume":"21","author":"E Canbay","year":"2014","unstructured":"Canbay E, Mizumoto A, Ichinose M, Ishibashi H, Sako S, Hirano M, et al. Outcome data of patients with peritoneal carcinomatosis from gastric origin treated by a strategy of bidirectional chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a single specialized center in Japan. Ann Surg Oncol. 2014;21(4):1147\u201352.","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"4123_CR61","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/j.ejso.2019.03.011","volume":"45","author":"Y Hao","year":"2019","unstructured":"Hao Y, Liu Y, Ishibashi H, Wakama S, Nishino E, Yonemura Y. Downstaging of lymph node metastasis after neoadjuvant intraperitoneal and systemic chemotherapy in gastric carcinoma with peritoneal metastasis. Eur J Surg Oncol. 2019;45(8):1493\u20137. https:\/\/doi.org\/10.1016\/j.ejso.2019.03.011.","journal-title":"Eur J Surg Oncol"},{"key":"4123_CR62","doi-asserted-by":"publisher","first-page":"153303382110363","DOI":"10.1177\/15330338211036310","volume":"20","author":"X Zhang","year":"2021","unstructured":"Zhang X, Huang H, Yang D, Wang P, Huang X, Hu Z, et al. Neoadjuvant intraperitoneal and systemic chemotherapy versus neoadjuvant systemic chemotherapy with docetaxel, oxaliplatin, and S-1 for gastric cancer with peritoneal metastasis: a propensity score matched analysis. Technol Cancer Res Treat. 2021;20:15330338211036310.","journal-title":"Technol Cancer Res Treat"},{"issue":"11","key":"4123_CR63","doi-asserted-by":"publisher","first-page":"3338","DOI":"10.1245\/s10434-017-6047-4","volume":"24","author":"B Badgwell","year":"2017","unstructured":"Badgwell B, Blum M, Das P, Estrella J, Wang X, Ho L, et al. Phase II trial of laparoscopic hyperthermic intraperitoneal chemoperfusion for peritoneal carcinomatosis or positive peritoneal cytology in patients with gastric adenocarcinoma. Ann Surg Oncol. 2017;24(11):3338\u201344.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"4123_CR64","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1245\/s10434-018-07140-7","volume":"26","author":"TE Newhook","year":"2019","unstructured":"Newhook TE, Agnes A, Blum M, Estrella JS, Das P, Ho L, et al. Laparoscopic hyperthermic intraperitoneal chemotherapy is safe for patients with peritoneal metastases from gastric cancer and may lead to gastrectomy. Ann Surg Oncol. 2019;26(5):1394\u2013400.","journal-title":"Ann Surg Oncol"},{"issue":"20","key":"4123_CR65","doi-asserted-by":"publisher","first-page":"6527","DOI":"10.3390\/jcm12206527","volume":"12","author":"AJ Jain","year":"2023","unstructured":"Jain AJ, Badgwell BD. Current evidence for the use of HIPEC and cytoreductive surgery in gastric cancer metastatic to the peritoneum. J Clin Med. 2023;12(20):6527. https:\/\/doi.org\/10.3390\/jcm12206527.","journal-title":"J Clin Med"},{"issue":"1","key":"4123_CR66","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1097\/01.sla.0000218089.61635.5f","volume":"244","author":"P Esquis","year":"2006","unstructured":"Esquis P, Consolo D, Magnin G, Pointaire P, Moretto P, Ynsa MD, et al. High intra-abdominal pressure enhances the penetration and antitumor effect of intraperitoneal cisplatin on experimental peritoneal carcinomatosis. Ann Surg. 2006;244(1):106\u201312. https:\/\/doi.org\/10.1097\/01.sla.0000218089.61635.5f.","journal-title":"Ann Surg"},{"issue":"7","key":"4123_CR67","doi-asserted-by":"publisher","first-page":"e368","DOI":"10.1016\/S1470-2045(19)30318-3","volume":"20","author":"M Alyami","year":"2019","unstructured":"Alyami M, H\u00fcbner M, Grass F, Bakrin N, Villeneuve L, Laplace N, et al. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. Lancet Oncol. 2019;20(7):e368\u201377.","journal-title":"Lancet Oncol"},{"issue":"1","key":"4123_CR68","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ejso.2020.05.021","volume":"47","author":"M Alyami","year":"2021","unstructured":"Alyami M, Bonnot PE, Mercier F, Laplace N, Villeneuve L, Passot G, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable peritoneal metastasis from gastric cancer. Eur J Surg Oncol. 2021;47(1):123\u20137. https:\/\/doi.org\/10.1016\/j.ejso.2020.05.021.","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"4123_CR69","doi-asserted-by":"publisher","first-page":"S271","DOI":"10.21037\/jgo-2020-22","volume":"12","author":"PH Sugarbaker","year":"2021","unstructured":"Sugarbaker PH, Van der Speeten K. PIPAC may work but more data is needed. J Gastrointest Oncol. 2021;12(1):S271\u20132.","journal-title":"J Gastrointest Oncol"},{"issue":"3","key":"4123_CR70","doi-asserted-by":"publisher","first-page":"270","DOI":"10.4143\/crt.2014.46.3.270","volume":"46","author":"OK Kwon","year":"2014","unstructured":"Kwon OK, Chung HY, Yu W. Early postoperative intraperitoneal chemotherapy for macroscopically serosa-invading gastric cancer patients. Cancer Res Treat. 2014;46(3):270\u20139.","journal-title":"Cancer Res Treat"},{"issue":"12","key":"4123_CR71","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1080\/17425247.2019.1693997","volume":"16","author":"PH Sugarbaker","year":"2019","unstructured":"Sugarbaker PH. Intraperitoneal delivery of chemotherapeutic agents for the treatment of peritoneal metastases: current challenges and how to overcome them. Expert Opin Drug Deliv. 2019;16(12):1393\u2013401. https:\/\/doi.org\/10.1080\/17425247.2019.1693997.","journal-title":"Expert Opin Drug Deliv"},{"key":"4123_CR72","doi-asserted-by":"publisher","first-page":"671","DOI":"10.3389\/fonc.2019.00671","volume":"9","author":"Z Sun","year":"2019","unstructured":"Sun Z, Liu H, Yu J, Huang W, Han Z, Lin T, et al. Frequency and prognosis of pulmonary metastases in newly diagnosed gastric cancer. Front Oncol. 2019;9:671.","journal-title":"Front Oncol"},{"issue":"1","key":"4123_CR73","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s12032-015-0718-4","volume":"33","author":"P Aurello","year":"2016","unstructured":"Aurello P, Petrucciani N, Giulitti D, Campanella L, D\u2019Angelo F, Ramacciato G. Pulmonary metastases from gastric cancer: is there any indication for lung metastasectomy? A systematic review. Med Oncol. 2016;33(1):9.","journal-title":"Med Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04123-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-04123-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04123-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T11:03:04Z","timestamp":1776769384000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-04123-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":73,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["4123"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-04123-5","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"assertion":[{"value":"5 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest or funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The current study has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Since this article is a literature review, no patient data has been collected, so informed consent is not required in this case.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"As the article is a literature review, no new patient data have been added.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}}]}}